Digital health player Akili has raised $110 million fourth-round funding, backed by a number of pharma groups, as it works towards extending its product range beyond its flagship EndeavorRx app.

Digital health company Akili has launched a non-prescription version of its attention-deficit hyperactivity disorder (ADHD) digital therapeutic EndeavorRx, that can be downloaded from the Apple ...